Sulfameter

Summary

Sulfameter (CHEMBL1200359) is an approved small-molecule antiinfective agent (ATC J01ED04); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01ED04
• Indications: 1 condition
• Chemistry: 280.31 Da · C11H12N4O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200359
Name	Sulfameter
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5326
ChEBI	CHEBI:53727
ATC	J01ED04
Molecular formula	C11H12N4O3S
Molecular weight	280.31
InChIKey	GPTONYMQFTZPKC-UHFFFAOYSA-N

SMILES: COC1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N

IUPAC name: 4-amino-N-(5-methoxypyrimidin-2-yl)benzenesulfonamide

ChEBI definition: A sulfonamide consisting of pyrimidine having a methoxy substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 2-position.

Pharmacological roles (ChEBI): antiinfective agent, renal agent, leprostatic drug.

Also known as: AHR-857, BAY-5400, Bayrena, NSC-683528, NSC-757874, SH-613, Sulfameter, Sulfamethoxydiazine, Sulfametin, Sulfametoxidiazina, Sulfametoxydiazine, Sulla

Patent coverage: 1,812 distinct patent families (4,963 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prelamin-A/C, Beta-lactamase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P00811	6.45	Potency	354.8	nM	CHEMBL_ACT_4668842

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).